Business Wire - June 1, 2005
The tuberculosis testing application of this technology was developed as part of Xenomics' joint venture with the National Institute for Infectious Diseases, "Lazzaro Spallanzani," in Rome. Because it was developed in Italy, an initial patent for the discovery was filed previously in that country followed by a broader European patent in recent weeks, in accordance with international patent laws. Significantly, the TB detection method also provides improved detection for another infectious disease, HIV, according to Dr. Randy White, CEO of Xenomics.
"It is tremendously rewarding for our scientific team to file this application on our TB detection technology with the U.S. Patent and Trademark Office," Dr. White said. "Our research involving these and other infectious diseases has already produced important new clinical data that demonstrates the potential to significantly transform, simplify and improve the fast-growing marketplace of DNA-based diagnostic testing, which currently is a $1.5 billion segment of the medical diagnostics industry."
The U.S. patent application signifies Xenomics' continued scientific progress in applying its Tr-DNA technology platform, which detects DNA material that traverses the kidneys and is eliminated in the urine. The Company is using this proprietary technology to develop a family of next-generation medical diagnostic tests based on its Tr-DNA technology. The Company believes that its Tr-DNA technology platform will enable more sensitive, accurate and affordable testing methods that can be conducted on simple urine samples, to create a wide range of biomedical applications, including prenatal tests for fetal genetic abnormalities, and for infectious diseases such as HIV and TB.
"Our mission at Xenomics is to develop and deliver practical diagnostic applications based on a safe, simple and effective urine sample," said Dr. White. "Our TB test that uses Tr-DNA is an excellent example. A urine sample is far easier to collect than sputum and the DNA-based test can be performed in a matter of hours instead of days required for the conventional microbiologic culture method. These same advantages apply to all of the tests under development at Xenomics."
About Xenomics, Inc.
Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a pending European patent for the same applications. The Company has organized a joint venture to conduct research on infectious disease detection with the National Institute for Infectious Diseases (Instituto Nazionale per le Malattie Infettive "Lazarus Spallanzani") in Rome, in the form of a new R&D company called SpaXen Italia, S.R.L. For more information, please visit http://xenomics.com. For more investor-specific information, including daily and historical Company stock quote data and recent news releases, please visit http://www.trilogy-capital.com/tcp/xenomics. To read or download the Company's Investor Fact Sheet visit http://www.trilogy-capital.com/tcp/xenomics/factsheet.html. To view an online video about Xenomics technology and products, visit http://www.trilogy-capital.com/tcp/xenomics/video.html. A TV news report about the Company's next-generation prenatal tests can be viewed at http://www.trilogy-capital.com/tcp/xenomics/ny1_video.html.
Forward-Looking Statements
Certain statements made in this press release are forward looking. Such statements are indicated by words such as "expect," "might," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Xenomics believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the periodic reports of Xenomics, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that Xenomics will not obtain approval to market its products, the risk that Xenomics' technology will not gain market acceptance, the risks associated with dependence upon key personnel, and the need for additional financing.
CONTACT: Xenomics, Inc.
Randy White, 212-297-0808
or
Trilogy Capital Partners, Inc. (Investor Relations)
Paul Karon, 800-342-1467
paul@trilogy-capital.com
SOURCE: Xenomics, Inc.
050601
BW050601
Copyright © 2005 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .